|
|
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial
Julien Taieb
,
Valérie Taly
,
Julie Henriques
,
Camille Bourreau
,
Laurent Mineur
,
et al.
Journal articles
inserm-03405591v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial
Julien Taïeb
,
Léonor Benhaim
,
Pierre Laurent Puig
,
Karine Le Malicot
,
Jean François Emile
,
et al.
Journal articles
inserm-02992943v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer
Alain Thierry
,
Brice Pastor
,
Ekaterina Pisareva
,
Francois Ghiringhelli
,
Olivier Bouché
,
et al.
Journal articles
hal-03649599v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer
Benoist Chibaudel
,
Franck Bonnetain
,
Christophe Tournigand
,
Marine Hug de Larauze
,
Armand de Gramont
,
et al.
Journal articles
hal-01211687v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A comprehensive overview of promising biomarkers in stage II colorectal cancer
Pauline Parent
,
Romain Cohen
,
Elie Rassy
,
Magali Svrcek
,
Julien Taieb
,
et al.
Journal articles
hal-03492180v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Fusions NTRK : une nouvelle piste dans les cancers digestifs ?
Kaïssa Ouali
,
Anna Pellat
,
Romain Cohen
,
Magali Svrcek
,
Frédérique Penault-Llorca
,
et al.
Journal articles
hal-02882231v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
Laurence Moureau-Zabotto
,
Jean-Marc Phélip
,
Pauline Afchain
,
Laurent Mineur
,
Thierry André
,
et al.
Journal articles
inserm-00376398v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
The immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study
Marine Jary
,
Wen‐wei Liu
,
Dongyao Yan
,
Isaac Bai
,
Andrea Muranyi
,
et al.
Journal articles
hal-03510003v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
Stefano Kim
,
Bruno Buecher
,
Thierry André
,
Marine Jary
,
François-Clément Bidard
,
et al.
Journal articles
hal-03130294v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study
Benoist Chibaudel
,
Thierry André
,
Christophe Tournigand
,
Christophe Louvet
,
Magdalena Benetkiewicz
,
et al.
Journal articles
hal-03492386v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency
R. Cohen
,
O. Buhard
,
P. Cervera
,
Elisabeth Hain
,
S. Dumont
,
et al.
Journal articles
hal-01628456v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status
Romain Cohen
,
Elisabeth Hain
,
Olivier Buhard
,
Agathe Guilloux
,
Armelle Bardier
,
et al.
Journal articles
hal-02419371v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Raphael Colle
,
Anna Radzik
,
Romain Cohen
,
Anna Pellat
,
Daniel Lopez-Tabada
,
et al.
Journal articles
hal-03492747v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
Florence Huguet
,
Thierry André
,
Pascal Hammel
,
Pascal Artru
,
Jacques Balosso
,
et al.
Journal articles
inserm-00383864v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
Benoist Chibaudel
,
Frédérique Maindrault-Goebel
,
Jean-Baptiste Bachet
,
Christophe Louvet
,
Ahmed Khalil
,
et al.
Journal articles
hal-01312777v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|